课题基金 / 基金详情

项目摘要

项目成果

SHING Yan CHIU的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):线粒体是通过代谢匹配维持有髓鞘轴突健康的动态细胞器,其中线粒体移动到高能量需求区域并在高能量需求区域暂停。在脱髓鞘疾病如多发性硬化症(MS)中,由于髓鞘的丢失而暴露出大面积裸露的轴突,因此能量需求大幅增加。作为响应,更多的线粒体移动到病变部位并固定在病变部位,导致轴突线粒体含量大幅增加。流行的假设是,轴突线粒体含量的增加是一种适应性变化,以保持适当的代谢,以保护轴突。然而,这种线粒体的增加也可能是适应不良的,并通过过量的自由基产生来破坏轴突。天平究竟朝哪个方向倾斜从未被测试过。随着线粒体成为MS发病机制中的关键参与者,确定这种众所周知的轴突线粒体含量增加是朋友还是敌人变得至关重要。最近,我们开始通过在髓鞘形成障碍的动物模型(Shiverer)中基因减少轴突线粒体含量的增加来解决这个问题。我们将Shiverer杂交到缺乏线粒体固定蛋白(syntaphilin)的背景中,该蛋白通常有助于轴突线粒体含量的增加。令人惊讶的是,syntaphilin的缺失显著延长了Shiverer突变体的预期寿命。基于这些生存数据,R21研究了线粒体锚定是否有助于脱髓鞘中的轴突杀伤,以及通过消除固定来增加线粒体移动性是否对脱髓鞘轴突具有神经保护作用。 在目标#1中,我们将使用免疫组织化学和形态学分析来观察缺乏syntaphilin的Shiverer小鼠的轴突是否受到保护。在Shiverer(与syntaphilin存在)中, 中枢神经系统不同区域的年龄依赖性轴突变性。我们将研究是否消除线粒体锚定延迟或减少这种年龄依赖性轴突变性。我们还将检测DRG中的syntaphilin,以直接测试过度的线粒体锚定是否会杀死脊髓中的轴突。 在目标#2中,我们将检查线粒体锚定的消除是否类似地保护EAE(MS的炎性脱髓鞘模型)中的小鼠。我们将在具有或不具有联嗜蛋白的小鼠中诱导EAE,以观察临床评分是否在无联嗜蛋白背景下得到改善。 结论:这个R21的建议探索了一个潜在的突破性的范例,在线粒体研究在MS.与现有的研究集中在线粒体作为上游退化变化的下游目标,我们可能已经查明了一个上游事件涉及线粒体动力学(过度锚定),导致下游退化。它进一步表明了一种令人兴奋的治疗可能性,即改变移动的与非移动的线粒体的比率可以深刻地改变疾病的进展。拟议的实验将确定是否有一个坚实的基础,为未来的R01应用。
英文摘要
DESCRIPTION (provided by applicant): Mitochondria are dynamic organelles that maintain the health of myelinated axons by metabolic matching, in which mitochondria move to and pause at regions of high energy demands. In demyelinating diseases such as multiple sclerosis (MS), there is a huge increase in energy demand as large areas of denuded axons are exposed by the loss of myelin. In response, more mitochondria move to and become immobilized at lesion sites, contributing to a large increase in axonal mitochondrial content. The prevailing hypothesis is that this increase in axonal mitochondria content is an adaptive change to maintain proper metabolism to protect axons. However, this mitochondrial increase could also be maladaptive and tip the scale to damage axons by excess free radical production. Which way the scale actually tips has never been tested. With mitochondria emerging as a key player in the pathogenesis of MS, it becomes critical to determine whether this well-known increase in axonal mitochondrial content is friend or foe. Recently we started to address this issue by genetically reducing the increase in axonal mitochondrial content in an animal model of dysmyelination (Shiverer). We interbred the Shiverer into a background lacking a mitochondrial immobilization protein (syntaphilin) that normally contributes to the increase in axonal mitochondrial content. Surprisingly, deletion of syntaphilin dramatically extends the life expectancy of the Shiverer mutant. Based on this survival data, this R21 explores whether mitochondrial anchoring contributes to axon killing in demyelination, and whether increasing mitochondrial mobility by elimination of immobilization confers neuroprotection on demyelinated axons. In Aim #1, we will use immunohistochemistry and morphologic analysis to see if axons are protected in Shiverer mice lacking syntaphilin. In Shiverer (with syntaphilin present) there is an age-dependent axonal degeneration in various regions in the CNS. We will examine if elimination of mitochondrial anchoring delays or reduces this age-dependent axonal degeneration. We will also transfect syntaphilin in the DRG to directly test if excessive mitochondrial anchoring kills axons in the spinal cord. In Aim #2, we will examine if elimination of mitochondrial anchoring similarly protects mice in EAE, an inflammatory demyelination model for MS. We will induce EAE in mice with or without syntaphilin to see if the clinical scores are improved in the syntaphilin-null background. Conclusion: This R21 proposal explores a potentially ground-breaking paradigm in mitochondrial research in MS. In contrast to existing research focusing on mitochondria as a down-stream target of upstream degenerating changes, we might have pinpointed an upstream event involving mitochondrial dynamics (excessive anchoring) that leads to downstream degeneration. It further suggests an exciting therapeutic possibility that altering the ratio of mobile to immobile mitochondria could profoundly alter disease progression. The proposed experiments will determine whether there is firm footing for a future R01 application.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Pathways to Excitotoxicity in Multiple Sclerosis Caused by Inappropriate Intrusion of an Axonal Mitochondrial Anchor Syntaphilin into Dendrites
  • 批准号:
    10219369
  • 项目类别:
  • 资助金额:
    $39.98万
  • 财政年份:
    2020
  • 负责人:
    SHING Yan CHIU
  • 依托单位:
Novel Pathways to Excitotoxicity in Multiple Sclerosis Caused by Inappropriate Intrusion of an Axonal Mitochondrial Anchor Syntaphilin into Dendrites
  • 批准号:
    10641019
  • 项目类别:
  • 资助金额:
    $39.98万
  • 财政年份:
    2020
  • 负责人:
    SHING Yan CHIU
  • 依托单位:
Novel Pathways to Excitotoxicity in Multiple Sclerosis Caused by Inappropriate Intrusion of an Axonal Mitochondrial Anchor Syntaphilin into Dendrites
  • 批准号:
    10034050
  • 项目类别:
  • 资助金额:
    $27.67万
  • 财政年份:
    2020
  • 负责人:
    SHING Yan CHIU
  • 依托单位:
Novel Pathways to Excitotoxicity in Multiple Sclerosis Caused by Inappropriate Intrusion of an Axonal Mitochondrial Anchor Syntaphilin into Dendrites
  • 批准号:
    10409730
  • 项目类别:
  • 资助金额:
    $39.98万
  • 财政年份:
    2020
  • 负责人:
    SHING Yan CHIU
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: